08:38 ETWorld's First Recombinant Botulinum Toxin Type A New Drug Received Marketing Approval in China: a Technological Revolution pioneered by Claruvis Pharmaceuticalprnewswire·Apr 28 at 07:39 AM浙江博锐生物制药股份有限公司科兴生物制药股份有限公司
Hesai 4Q25 First Take: Results again showed high shipment growth driven by price compression. The company protected margins via solid cost control and issued upbeat 2026 shipment guidance. I. 4Q25 results: volumes up, prices down, profitability remained resilient 1) Revenue: RMB 1.0 bn, +39% YoY. This was at the low end of prior guidance (RMB 1.0–1.2 bn) and slightly below the RMB 1.08 bn consensus. Shipments: 631k units, +184% YoY, beating guidance (600k) and the 619k consensus. Growth was driven by robot LiDAR (80k units, above the 50k expected) and the continued ramp of ADAS LiDAR (550k units). ASP: RMB 1,557, down 51% YoY and 13% QoQ, well below the RMB 1,718 the market expected. This directly explains the revenue miss vs. consensus. Dolphin Research sees three main drivers of the faster ASP decline: a) Product mix shift: the low-priced 'thousand-yuan' ATX rose from 70% in Q3 to ~80% in Q4. It accelerated the replacement of the older AT128, which sells for multiples of that price. b) Proactive discounts: to defend share, the co. offered ATX discounts to key customers in Q4. This weighed on blended pricing. c) Robot mix: within robot shipments, the lower-priced JT series likely accounted for a higher share. This further dragged ASP. 2) Despite a sharp ASP decline, HSAI showed resilient profitability. Margin held up better than feared. GPM: 41.0%. This was above the 39.7% consensus and the company's 40% guide. We attribute this to scale benefits from higher volumes and ongoing cost downs from in-house ASICs, supply-chain optimization, and factory automation. These gains offset pricing pressure. 3) Net profit at the top end: GAAP net profit was RMB 150 mn, at the high end of guidance (RMB 70–170 mn). This was boosted by interest income and other gains (~RMB 120 mn). In Q4, HSAI received ~$6.4 mn (~RMB 45 mn) in IP arbitration compensation from Ouster. Excluding these items, core OP was ~RMB 40 mn (GP minus core Opex), slightly below the RMB 60 mn expected, mainly due to higher R&D and S&M QoQ. Overall, expense control remained disciplined. II. 2026 guidance: shipment targets raised materially Mgmt is upbeat on 2026, guiding well above prior market expectations. The tone signals confidence in volume growth. 2026 shipment guide: 3.0–3.5 mn units (+185%–216% YoY). This is a major step-up from the prior 2.0–3.0 mn range and is well above the 2.66 mn street. To support this, the co. plans to double annual capacity to 4.0 mn units from 2.0 mn in 2025. Q1 pricing likely stable to up: 2026 Q1 net revenue guidance is RMB 650–700 mn (+24%–33% YoY). Given Q1 is typically a seasonal trough for autos (about 12% of annual shipments historically), the midpoint of the full-year guide implies ~393k units in Q1. Back-solving implies a blended Q1 ASP of ~RMB 1,675, slightly above 4Q25's RMB 1,557. We think this reflects slower passenger-car LiDAR shipments in Q1 and a higher mix of higher-priced robot/industrial LiDAR. $Hesai(HSAI.US) $HESAI-W(02525.HK)Mar 24 at 06:51 AMHSAI-3.18%688363+2.75%
After the "glass glue war," GIANT BIOGENE shows its first signs of growth anxietyWallstreetcn·Mar 19 at 10:28 PM02367-1.23%159849-0.61%
National Health Commission: Beauty institutions, hair salons, nail salons, and other lifestyle-related businesses are strictly prohibited from conducting "light medical beauty" projectsWallstreetcn·Feb 10 at 01:53 AM300896+3.30%688366+1.91%
Hesai (3Q25 Minutes): Lidar shipments are expected to reach at least 2 million to 3 million units by 2026Nov 11, 2025 at 06:58 PM688363+2.75%IPO+2.49%
Hesai: Tesla 'Disdain'? Still Growing Wildly Towards the SunNov 11, 2025 at 08:16 AMHUAWEI01810-2.63%
CIIE Direct Hit: AI Reshapes the Health EcosystemWallstreetcn·Nov 6, 2025 at 10:40 PM688363+2.75%06618-1.80%
Bloomage Biotech Zhao Yan's company and others established a HuiTou private equity fund management company36Kr·Oct 28, 2025 at 10:16 PM688363+2.75%
HuaLong Securities: Technical support, industry chain synergy, and new trends in medical beauty applications; focus on potential layout opportunities in collagenZhitong·Oct 24, 2025 at 02:40 AM688363+2.75%
Research institutions extract new anti-inflammatory and anti-aging components from various plantsZhitong·Oct 19, 2025 at 03:18 AM688363+2.75%
C&S and Bloomage Biotech's joint venture biotechnology company has been deregisteredZhitong·Oct 16, 2025 at 01:41 AM688363+2.75%002511+3.88%
Shenwan Hongyuan: It is expected that the overall performance of the cosmetic medical beauty industry in Q3 2025 will meet expectations, with a continued upward trend in Q4Zhitong·Oct 16, 2025 at 01:15 AM688363+2.75%600315+2.31%
Bloomage Biotech: Controlling shareholder increased holdings by 0.94%Zhitong·Sep 30, 2025 at 06:59 AM688363+2.75%
